Treatment for the opiate crisis – creating another crisis ? – who could have seen this coming ?

Kids’ Exposure to Buprenorphine Skyrockets

https://www.medscape.com/viewarticle/898671

The number of children aged 19 years and younger exposed to buprenorphine, an opiate widely prescribed to treat pain and opioid use disorder, has been rising since 2007, according to a study published online June 25 in Pediatrics.

Researchers led by Sara Post, MS, from the Center for Injury Research and Policy, The Research Institute, Nationwide Children’s Hospital, Columbus, Ohio, report that the overall exposure rate per million children increased by 215.6% during 2007 to 2010, going from 6.4 to 20.2. After dropping by 42.6% during 2010 to 2013 to 11.6 per million, it rose again by 8.6% to 12.6 per million in 2016.

Post’s group found that during 2007 to 2016, poison control centers in the National Poison Data System received reports of 11,275 children and adolescents with exposure to buprenorphine. Overall, 53.1% of exposures occurred in boys, and the mean age of affected children was a surprising 3.8 years.

Most of the exposures took place in residences, involved a single product, and occurred by ingestion. Overall, 21.2% of contacts with the drug had serious medical consequences such as respiratory depression, bradycardia, hypotension, and cyanosis, and 11 affected youngsters died.

Earlier this year, Medscape Medical News reported that pediatric opioid-related admission to intensive care units almost doubled during 2004 to 2015.

“Although buprenorphine is important for medication-assisted treatment of opioid use disorder, pediatric exposure to this medication can result in serious adverse outcomes,” according to senior author Gary A. Smith, MD, DrPH, from the Department of Pediatrics, College of Medicine, at The Ohio State University in Columbus.

The study looked at the age groups younger than 6 years, 6 to 12 years, and 13 to 19 years. Overall, 86.1% of contacts with the drug occurred in the youngest group, and 89.2% of contacts were reported as unintentional.

For single-substance exposures (97.3%), children younger than 6 years had greater odds of hospital admission and a serious medical outcome than adolescents aged 13 to 19 years. In those younger than 6 years, 48.1% of exposures led to hospital admission and 21.4% had a serious medical outcome, with seven deaths reported in this age group.

Adolescents aged 13 to 19 years made up 11.1% of exposures, and in this age category 77.1% of exposures were intentional, including 12.0% for suspected suicide attempts. More than a quarter of exposures (27.7%) involved the use of more than one substance. In this age group, 21.5% of exposures resulted in hospital admission and 22.0% in a serious medical outcome, including four deaths, all of which involved other substances such as alcohol or benzodiazepines.

But the exposure rate per million adolescents has declined: after increasing by 195.0% from 2.0 in 2007 to 5.9 in 2010, the rate dropped by 47.5% to 3.1 from 2010 to 2016, despite the widespread prescribing of this drug. As for the temporary overall drop in exposures during 2010 to 2013, the authors write, “One factor may be a shift in buprenorphine prescriptions to a population less likely to have young children in the home.”

According to the authors, prevention strategies are urgently needed and should be tailored to different stakeholders. Manufacturers, for instance, should use unit-dose packaging for buprenorphine products to reduce the chance of unintentional exposure. “Safe storage of all opioids, including buprenorphine, is crucial,” Smith said. “Parents and caregivers who use buprenorphine need to store it safely: up, away, and out of sight in a locked cabinet is best.”

In addition, healthcare providers need to warn childcare providers of the dangers of buprenorphine exposure and give instructions on safe storage and disposal. Adolescents should be informed of the risks of substance abuse and misuse. “Suspected suicide accounted for 12% of teen exposures, highlighting the need for access to mental health services for this age group,” Smith said.

One author was supported by a research stipend from the Center for Injury Research and Policy at Nationwide Children’s Hospital, funded by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and the Child Injury Prevention Alliance. One author has been retained to comment on a legal case involving buprenorphine. The other authors have disclosed no relevant financial relationships.

husband called Winn-Dixie corporate and they said the Pharmacist was just outright lying to you !

My husband was getting his medication at Winn-Dixie and had been getting it for several years and after 3 weeks of waiting the pharmacist told him he no longer fit the criteria and he asked what was that he said he didn’t know but corporate told them so my husband called corporate and they said he was just outright lying to you and then when he told us the pharmacies only get so much medication in the pharmacist is deciding who he wants to give it to and who he doesn’t want to give it to


In FL. you can only get 3 days worth up to 7 days if they had surgery. Primary Care Dr can’t write for any kind of narcotic. My husband was getting his medication at Walmart and the pharmacist contacted his doctor and wanted him to drop one pill every month until he was totally off of them. Well then what do you do? I don’t know if this is just in the State of Florida or in the whole country but each pharmacist carry their own license and it’s up to them if they want to fill your medication or not. My husband just got cut from 140 oxycodone 30 mg down to 112.


Walmart is no longer going to carry any type of narcotic. When he went to the doctor this past month they gave him a prescription for Narcan. They gave all of the patients a prescription


I was at a FL Board of Pharmacy (BOP) meeting in June 2015 and a chronic pain doc asked the board’s attorney if a pharmacist lying to a pt is against the pharmacy practice act (unprofessional conduct) and the attorney’s answer … paraphrase – there is nothing in the practice act that addresses that … apparently in FL the bar to be crossed – must be awful high – for the BOP to consider a pharmacist’s action guilty of unprofessional conduct ?

I have not read the FL Pharmacy practice act but most practice acts states that a pharmacy MUST STOCK MEDICATIONS that are commonly used in their market place… so any pharmacy stopping the stocking a  commonly used medication could be putting their pharmacy license at risk and/or getting fined.

Since the majority of legal opiates are prescribed/sold to those with some degree of chronic pain… could a store or chain that has decided to stop stocking opiates as a store/company policy be directly/indirectly  in violation of the Americans with Disability Act and Civil Rights Act and be guilty of a civil rights violation against a protect class of people/pts ? Something for a class action law firm and our court system to decide ?

 

The Myth of Morphine Equivalent Daily Dosage

The Myth of Morphine Equivalent Daily Dosage

https://www.medscape.com/viewarticle/863477

For far too many years, pain researchers and clinicians have relied on the concept of the morphine equivalent daily dosage (MEDD), or some variant of it, as a means of comparing the “relative corresponding quantity” of the numerous opioid molecules that are important tools in the treatment of chronic pain. This concept dates back to the mid-1980s, first appearing in the cancer pain treatment guidelines by Portenoy and colleagues,[1] and has subsequently been used empirically and clinically for a variety of purposes.

For example, researchers have relied on non-empirically derived “equivalent dosages” as a means to facilitate research in which opioid consumption serves as a dependent variable. Clinically, opioid “conversion” tables have been routinely used when switching a patient from one opioid to another. And, most unfortunately, opioid prescribing guideline committees have relied on this concept as a means of placing (usually arbitrary) limits on the levels of opioids that a physician or other clinician should be allowed to prescribe. Although these guidelines typically bill themselves as “voluntary,” their chilling effect on prescribers and adaptation into state laws[2] makes calling them “voluntary” disingenuous.

Although some scientists and clinicians have been questioning the conceptual validity of MEDD for several years, a recent study[3] has indicated that the concept is unequivocally flawed—thereby invalidating its use empirically and as a tool in prescribing guideline development. This analysis determined that a fundamental inadequacy of the MEDD concept is the lack of a universally accepted opioid-conversion method. The authors used survey data from pharmacists, physicians, nurse practitioners, and physician assistants to estimate daily morphine equivalents and found great inconsistency in their conversions of hydrocodone, fentanyl transdermal patches, methadone, oxycodone, and hydromorphone—illustrating the potential for dramatic underdosing or, in other cases, fatal overdosing.

Regarding the use of MEDD in research, our suspicion is that many pain investigators have known about the problems with this prodigiously flawed concept for many years. For example, in a 1991 Australian review of the polymorphic metabolism of opioids,[4] the authors concluded that “Pharmacogenetics may play an important role in explaining the wide variability of the clinical response to many opioid drugs.” Yet, a quarter of a century later, MEDD remains routinely used in pain research worldwide. Given that invalid dependent variables in research result in invalid findings, our hope is that investigators will begin to conduct studies comparing morphine with morphine, hydrocodone with hydrocodone, and so on—as opposed to relying on the standard (and far more convenient) approach of MEDD.

Implications in the Clinic

Clinically, prescribers need to use this information regarding the flawed MEDD concept to begin practicing dosage-switching and opioid rotation in a more thoughtful and scientific manner. Thus, even if the charts suggest that 1 mg of oxycodone is the “equivalent” of 1.5 mg of morphine, the practice of opioid rotation based on the concept of pharmacogentic homogeneity needs to be seriously reconsidered.

Furthermore, the evidence supporting pharmacogenomic differences among patients is mounting[5,6] and needs to be carefully weighed before labeling a patient who requires 30 mg of morphine rather than the prescriber’s “standard” of 10 mg in order to achieve adequate analgesia as an “addict.” Patients with chronic pain (particularly that of noncancer origin) who are reliant on opioid analgesia are already sufficiently stigmatized and marginalized[7] to allow this type of practice to continue to be the norm.

Although the use of MEDD in research and, to a greater extent, in practice, is probably due to unawareness of its inaccuracy, we posit that the use of MEDD by recent opioid guideline committees (eg, the Washington State Opioid Guideline Committee[8] and the Centers for Disease Control and Prevention Guideline Committee[9]) in the drafting of their guidelines is based more heavily on disregarding available evidence rather than ignorance. Furthermore, their misconduct in doing so has been more pernicious than the use of MEDD by researchers and individual clinicians, because these guidelines widely affect society as a whole as well as individual patients with persistent pain syndromes. We opine that these committees are strongly dominated by the antiopioid community, whose agenda is to essentially restrict opioid access—irrespective of the lack of data indicating that opioids cannot be a useful tool in the comprehensive treatment of carefully selected and closely monitored patients with chronic pain.

Although we emphatically agree that opioid analgesia should not be the first-line treatment for chronic noncancer pain, when other nonopioid treatments have either failed, are contraindicated medically or owing to behavioral and emotional factors, or are inaccessible because of the health insurance industry’s refusal to cover them (irrespective of their established evidence-bases), opioids should be considered. Guidelines that contain language suggesting that alternative treatments are regularly available when this is not the case are shortsighted and troubling.

Recently, we published an article in the Journal of Pain Research titled “The MEDD Myth: The Impact of Pseudoscience on Pain Research and Prescribing-Guideline Development,”[10] with Dr Jacqueline Pratt Cleary as our coauthor. This article goes into considerably more detail regarding the clinical and ethical imbroglio that we address in the current brief article, and as an open-access publication, the Journal of Pain Research encourages readers to access the full text at no cost here. We feel that the healthcare community must learn more about the need to work toward a paradigmatic revision in the consideration of opioids in research, clinical practice, and prescribing guideline development.

 

This individual committed suicide this morning because the pain was overwhelming

A twitter follower tweeted the following this morning at 4:27 AM: (Name and handle withheld)

Last tweet don’t bother responding I won’t be here. Or anywhere thanks for no one responding to my cry for help

This individual committed suicide this morning because the pain was overwhelming. HOW LONG ARE WE AS A SOCIETY GOING TO IGNORE CHRONIC PAIN SUFFERERS IN THIS BOGUS OPIOID HYSTERIA?
Don’t you understand that it only takes a split second to become a person with chronic pain? As citizens, we need to rise up against the war on pain.

TN: As of July 1, if you have a prescription for opioid drugs, you’ll see some changes when you go to the pharmacy

Here’s what new Tennessee opioid restrictions mean at your doctor’s office and pharmacy

https://www.knoxnews.com/story/news/health/2018/06/29/tennessee-opioid-prescription-law-pharmacy/746208002/

As of July 1, if you have a prescription for opioid drugs, you’ll see some changes when you go to the pharmacy.

That’s the date legislation related to Gov. Bill Haslam’s sweeping TN Together opioid reform takes effect.

Haslam budgeted more than $30 million in state and federal funds to attack the opioid epidemic through prevention, treatment and law enforcement.

More: Haslam signs TN Together, gives lifeline to state beset by opioid epidemic

Revolving door of despair: Drugs land more women behind bars

Election 2018: What do Tennessee candidates say about the opioid crisis?

Limits on supply, strength

The biggest change has to do with how much of a drug you can get and when.

Under the new law, pharmacists can only partially fill a prescription for no more than half of the number of days it’s written for.

And there are limits on prescriptions, too: General prescriptions are limited to a 10-day supply (and no more than 500 cumulative morphine milligram equivalents). Prescriptions after surgery are limited to a 20-day supply (maximum 850 cumulative MMEs). “Medical necessity” prescriptions are limited to a 30-day supply (maximum 1,200 cumulative MMEs). This law technically takes effect July 1, but it won’t be mandated until Jan. 1, 2019, to give pharmacies a chance to update their software.

Checking the database

When you bring an opioid prescription to be filled, the pharmacy is required by law check the Controlled Substance Monitoring Database, which logs each time you fill a prescription for a controlled substance. The database has to be checked when you first bring a prescription to a pharmacy, and then again at least once every six months as long as you’re getting refills.

The country is in the midst of an opioid epidemic. Did the FDA play a role in how we got here? Ayrika Whitney/USA TODAY NETWORK – Tennessee

Doctors’ documentation

When your doctor writes you a prescription for an opioid drug, the law now requires he or she document the specific reasons you’re getting the drug, as well as the fact that you’re getting it with informed consent — your prescriber has warned you it can be addictive.

Three-day supplies less restricted

However, doctors can write (and pharmacies can fill) opioid prescriptions for a three-day (or less) supply (maximum 180 MMEs) without these restrictions.

No ‘gag’ on pharmacists

Pharmacists no longer have any limits on discussing opioid-related issues with customers, including risks, effects and characteristics of the drugs; what to expect when you use it; the proper way to use it; and cost, with insurance or cash.

Some prescriptions exempt

Some prescriptions are exempt from the requirements and limits, though doctors must still write a diagnosis code and “exempt” on them: Prescriptions for people who are getting palliative cancer treatment or hospice care; who have sickle cell disease; who are inpatients at licensed facilities; who are seen by doctors who meet the state requirements to be “pain management specialists”; who were treated with opioids for 90 days or more; who have severe burns or “major physical trauma”; and who are on methadone, buprenorphine or naltrexone, which are drugs used to assist recovery from addiction.

Initially, the legislation was more restrictive — prompting concern from pharmacists that it would prevent “legitimate patients” from being able to get needed prescriptions and put a burden on pharmacists, said the Tennessee Pharmacists Association, which lobbied legislators for some changes.

But the organization said in a statement that decreasing the prescription drug supply must be combined with access to treatment and recovery services, or it may increase both the number of people using illicit street drugs and the number of pharmacy burglaries/robberies.

“While this legislation is well-intended, TPA remains concerned about the unintended consequences of the legislation on patients and the pharmacy profession,” the Tennessee Pharmacists Association said. “Decreasing the overall epidemic of prescription drug abuse and reducing patients’ risk of dependence are commonly shared goals of all pharmacy professionals and Tennesseans. However, the need for patient access to treatment and recovery services has never been greater, and our state must continue to seek solutions which help our patients struggling with dependence and addiction to get the help they desperately need.”

This is the first time that I have heard about this… but.. then again.. I don’t live in TN. I think that I need to place the state of TN and all the bureaucrats that are in charge of protecting the citizens of TN. at the TOP OF MY MORON LIST !  I just hope that other states don’t take TN’s policies as a guideline for other states to follow.

It sure sounds like the state of TN is only interested in addiction… those who have chronic pain issues .. they are left to deal on their own… if the numbers are correct…  it appears that chronic pain pts will be limited to 40 MME/day…  that is 4 Vicodin 10/day… I don’t think that would allow a Fentanyl patch 12 mcg nor would it allow the smallest Morphine SR 15 q 8 hrs.  This is LESS THAN HALF OF WHAT THE CDC GUIDELINES STATED FOR ACUTE PAIN..

USA TODAY reporter “wants your denial of pain management story “

If you suffer from chronic pain, I’d like to know how the state and federal government response to the opioid epidemic has affected you. DM me or email jodonnell@usatoday.com

 

 

article now published

https://amp.usatoday.com/amp/727015002

 

Man claims Walgreens refused to fill valid prescription, slandered him to police

Man claims Walgreens refused to fill valid prescription, slandered him to police

https://cookcountyrecord.com/stories/511466180-man-claims-walgreens-refused-to-fill-valid-prescription-slandered-him-to-police

CHICAGO — A man is suing Walgreens and a pharmacist for alleged professional negligence, slander and vicarious liability.

Erron Fisher filed a complaint June 19 in Cook County Circuit Court, alleging the defendants intentionally made false statements to the police to stop providing him with prescription drugs.

According to the complaint, Fisher was refused a refill of his medication on June 18, even though he purportedly gave the defendants valid prescriptions from a physician.

The plaintiff claims he was falsely accused of receiving and using drugs illegally. As a result, Fisher said he suffered grief, humiliation and damage to his reputation.

Fisher said he holds defendants responsible for allegedly refusing to fill a valid prescription, making statements of a criminal offense that were untrue to retaliate and harm another person and providing medical information to third parties without a warrant or legal justification.

The plaintiff requests a trial by jury and seeks a judgment for damages greater than $50,000. He is represented by Erron Fisher of Fisher & Lamonica PC in Chicago.

A new “opiate crisis”… causing more people to suffer and die ?

Injectable opioid shortages put hospitals on brink of public health crisis

www.whyy.org/articles/injectable-opioid-shortages-put-hospitals-on-brink-of-public-health-crisis/

As the director of pharmacy at Penn Presbyterian Medical Center, Neshaminy Kasbekar used to place orders for injectable opioids a couple of times a week so that the staff would have a week’s supply on hand at any one point.

Now, she’s placing orders every day.

“I’m scrambling right now,” she said.

The hospital is getting 30 percent less injectable morphine, fentanyl, and Dilaudid than it did a year ago.

That’s when a Pfizer manufacturing plant in Kansas cut back production due to quality issues and plant upgrades. Pfizer produces 60 percent of the country’s injectable opioids.

As they wait for supplies to stabilize, Kasbekar and her staff have gotten creative. They’ve purchased injectables in higher concentrations and bigger vials, using those to make smaller measures that they then send to the floors.

They are also rationing injectable opioids for all but the sickest patients — those who are in intensive care or who are undergoing surgery. For the rest, Kasbekar and her staff are encouraging the use of other medications, including oral painkillers or higher doses of over-the-counter remedies such as Tylenol or nonsteroidal anti-inflammatory drugs.

Some smaller hospitals have had to discontinue certain elective procedures because they couldn’t provide injectable painkillers for the patients. That hasn’t happened at Penn, Kasbekar said, but it is more difficult to get what’s needed.

“We’re not at a point where we’ve completely run out, and we’re in trouble,” she said. “But we are concerned that it’s coming — three, four months from now.”

Other hospitals in the region, including Temple, have also experienced shortages; like Penn, they are finding ways to maintain patient care. But getting an adequate supply from other manufacturers — including Akorn, Fresenius Kabi USA, and Hikma (formerly West-Ward Pharmaceuticals) — has been a challenge because those companies don’t have the capacity to fill the void Pfizer has left.

“We’re making progress in mitigating the shortages,” said Matthew Kuhn, a spokesman for Fresenius Kabi, “but given the high demand and limited supply of these specialized drugs, we expect availability of injectable opioids to be constrained and shortages to persist for months.”

In a statement on its web site, Hikma points to controlled substance quotas by the Drug Enforcement Administration for limiting its ability to increase supply.

In the meantime, Kazbekar and her staff continue to meet daily, sometimes twice a day. Given how fast everything is moving, she worries about the possibility of someone making a deadly mistake.

“We’re changing out product on the floors, we have concentrations that are changing, and so, as a result, it could potentially lead to medication errors,” she said. “So we’re really trying to be thoughtful in how we’re doing this, and the manufacturers aren’t really leaving much room for that.”

Pfizer recently sent hospitals a memo explaining how to filter injectable medications that had been held back due to potential particle contamination. The company doesn’t expect supplies to return to normal levels until the first quarter of 2019.

Databases key to Trump’s crackdown on opioids

Databases key to Trump’s crackdown on opioids

The databases are helping to reduce opioid prescriptions, which have fallen by nearly a third since 2011.

https://www.politico.com/story/2018/06/29/databases-key-crackdown-on-opioids-686879

Bolstered by harsh law-and-order rhetoric from President Donald Trump and his aides, police around the country are using electronic databases to unleash a vast crackdown on opioid abusers and the allegedly crooked doctors who sustain them.

The databases are helping to reduce opioid prescriptions, which have fallen by nearly a third since 2011. Police and disciplinary boards use the records systems to roll up “pill mills,” tag patients who “doctor shop” for multiple pills, and warn doctors about prescribing patterns that stray from norms.

Analysis of that data was instrumental in what Attorney General Jeff Sessions described Thursday as the biggest health care fraud crackdown in Justice Department history. Among the 601 individuals indicted were 76 doctors charged with allegedly illegal prescribing or distributing opioids and other narcotics.

Yet it’s unclear the databases do much to help addicted patients. Deaths from illegal opioids like heroin and fentanyl have skyrocketed even as fewer prescription opioids are dispensed — and there’s evidence that thousands of prescription users cut off by fearful doctors are turning to these dangerous street drugs, or being left to suffer. Many addicted patients end up in legal trouble before they are offered help.

Now, civil rights advocates and medical groups are arguing the databases should be used to identify problem patients and get them into treatment. The American Medical Association calls for the databases to be placed under health departments rather than the police agencies and disciplinary boards that control most of them.

The prescription drug monitoring programs “were designed to find those bad doctors — and that kinda shifted at one point to also find those bad patients,” said Corey Davis, a lawyer with the Network for Public Health Law. “It’s in the DNA of them.”

Civil rights activists see such use of the databases as a continuation of a flawed “war on drugs” mentality.

“Law enforcement for easy, warrantless demand [of prescription drug data] keys up a debate as to whether we want to treat this as a public health problem, or a problem we can jail our way out of,” said Nate Wessler, an ACLU lawyer. “Decades of experience shows us it’s impossible to prosecute our way out.”

A powerful tool for law enforcement
Law enforcement’s power to use the databases is truly staggering. In many states, cops can trawl through medical records in search of illicit prescriptions with only slight suspicions of malfeasance.

In 23 state and territory programs, police merely have to be actively investigating a case to check the programs, according to a Brandeis University center that tracks the databases. And doctors often find themselves in the crosshairs.

“There’s really no limits placed on investigators’ ability to access” the information, said lawyer Henry Fenton, who represents a California doctor investigated through that state’s database.

With Trump and Sessions saying some drug pushers deserve the death penalty, advocates say the databases have become tools for intimidation and a boon for investigations by police and professional disciplinary boards.

Law enforcement agencies increasingly use the databases — and aggressively. From 2013 to 2016, the last year for which statistics are available, law enforcement agencies in 42 states conducted well over 2 million searches of the databases, according to a POLITICO review of state-level data. The searches increased more than fourfold in a subset of 18 states from 2011 to 2015.

The tallies probably underestimate database use, as the figures record each time a doctor prescribes a controlled substance. Many state programs automatically ping either law enforcement or state regulatory boards when certain prescription limits are breached.

Given the enormity of the opioid crisis, prosecutors and medical regulators feel they are right to hold clinicians’ feet to the fire.

“Doctors have to be held accountable,” said Michael Morrissey, district attorney of Norfolk County, Mass. “I think it helps to know there are eyes on them.”

In some jurisdictions — like Norfolk County — authorities investigating overdoses have referred cases to professional boards, which can potentially strip a doctor’s license.

Police use of the programs varies widely from state to state. Oklahoma authorities queried that state’s database 10 times more than police in neighboring Texas in 2015, for example. The Oklahoma queries result in criminal charges against 7 to 10 providers a year, said Mark Woodward, spokesman for the state’s Bureau of Narcotics, and investigations of 50 to 100 patients suspected of doctor shopping, forging prescriptions, or street sales.

The programs are effective at providing leads to investigators, initially by pointing out “statistical outliers” — unusual use patterns that may indicate pill mill doctors, said Adam Overstreet, formerly a federal prosecutor in Alabama.

The programs have been so good at detecting pill mills, in fact, that the problem may be subsiding. “I think we’re pretty much beyond” pill mills, said Morrissey. His region’s problems now stem mostly from inattentive doctors and patients who sell their prescribed drugs, he said.

Others think prosecutors are just getting started. “We’re still in the middle of this push,” Overstreet said. “I haven’t seen any signs of it slowing down.”

Policymakers at all levels are exploring further expansion of law enforcement and regulatory board use of the databases. Earlier this year, for example, Sen. Bill Cassidy introduced a bill that would condition HHS grants to prescription drug monitoring programs on their capacity to automatically report suspicions to authorities.

State policymakers have also bolstered police use of the prescription data. Last year, Rhode Island enacted a law allowing designated officers to use the state database without a warrant. The state’s attorney general, Peter Kilmartin, dismissed opposition from local medical and civil liberties groups.

“Maybe the question we should be asking is, ‘What are the doctors trying to hide?’” he said.

In January, Anne Arundel County Executive Steven Schuh called on the Maryland state legislature to make monitoring data more easily available to law enforcement.

Investigators’ targets “are the dregs of the profession, the bottom of the barrel,” Schuh said. Investigators’ use of the Maryland database had already quintupled from 2014 to 2016.

Until this year, the courts had generally ruled that patients had little expectation of privacy and that the Constitution did not require search warrants for use of the databases. That position may be imperiled, however, by late June’s Supreme Court decision in Carpenter vs. United States. The high court ruled in that case that a search warrant was required for authorities to peruse cell phone location data. By analogy, lower-court judges might find that highly sensitive prescription data is similarly sensitive, said the ACLU’s Nate Wessler.

Overstreet disagreed: Pharmaceuticals are already tightly regulated, and people have lower expectations for privacy, he said.

 

Monitoring programs were created for drug enforcement
From their beginning, the drug prescription databases were designed for use by law enforcement and medical and pharmaceutical licensing boards.

California established the forerunner of the drug databases in the 1930s, and other states followed suit with analog prescription-tracking systems: Doctors filled out their scrips on special paper pads that dispensed orders in triplicate. Patients then took the prescription to their pharmacist, who retained one copy and sent another to the database.

More and more programs were established as medicine went digital. Only one state, Missouri, has not established a program — and many of its counties and cities have banded together to create their own patchwork system.

In theory, the programs have treatment, as well as policing, applications: Doctors and pharmacists can use the programs to identify patients taking too many painkillers, and to guide treatment. But access is often an arduous process for doctors, who frequently must exit their digital health records and log into the program separately.

Even after clinicians get into the programs, they often don’t know how to interpret the results. The data don’t come with advice on how to treat patients with a substance use problem, or the availability of clinicians who can handle their problems.

The programs “were never designed for clinicians to check them,” said Davis, the public health lawyer, who has researched their history. Meanwhile, it is “trivial” for law enforcement to pull them up, he said.

For at least some health care workers, evidence that a patient has a problem with a controlled substance means that it’s time to call the authorities. A focus group study of Wisconsin pharmacists published in January found that they were inclined to solve problems by involving the authorities, whether out of fear or conviction.

“You basically have to call 911,” said one focus group participant. “This is not the time and place to be discussing their treatment options. It is the time to get them to jail.”

Clinicians have long complained that the threat of official sanction may dissuade doctors from prescribing some medically legitimate opioids. Patients are complex, they argue; some may tolerate and require high doses of opioids without abusing the drugs. But it’s a brave doctor who can stand up to the prospect of official sanction.

In a December newsletter, the outgoing president of the New York state medical society described the chilling effect of recent warning letters sent by the state bureau of narcotics enforcement.

“Many physicians receiving these letters expressed concern that they felt at risk for … prosecution despite treating their patients in a way they believed was medically appropriate to the patient’s condition,” wrote Charles Rothberg, the president. Officials denied that intimidation was their goal, he said.

The threat of investigations may bring unintended consequences, says critics. If doctors don’t deliver pain medication to patients who need it, the patients may seek out illicit drugs like heroin and fentanyl. The degree to which this already is happening is a matter of debate.

While the mortality rate from prescription drug overdoses is falling, heroin and fentanyl deaths are still rising. A recent review in Annals of Internal Medicine found some evidence that such overdoses increased after the implementation of a prescription drug monitoring program, and said evidence the programs reduce opioid overdoses wasn’t convincing.

Law enforcement vociferously denies any chilling effect on legitimate prescriptions for pain patients.

“Doctors who are practicing good medicine, they’re doing everything they need to do … they’re keeping good records, they’re monitoring for signs of diversion, even if they do have a high number [of prescriptions], they’ll still be safe,” said Overstreet.

Enforcement growing
Prosecutor Morrissey, in Massachusetts, says that state troopers query the prescription drug monitoring program every time there’s a death to find out which doctor last prescribed opioids to the deceased person, and refer the information to the state licensing board.

“Doctors play an important role — they have to be held accountable,” he said. Two or three doctors have turned in their licenses rather than face the board’s scrutiny, he said. Morrissey concluded that the doctors were “a soft touch … If they can’t live up to the scrutiny of their peers, shame on them.”

Clinicians in his state don’t see things that way. “I’m not sure I’d like my first corrective action to be the board of registration,” said Cheryl Bartlett, CEO of New Bedford Community Health Center. Bartlett, a former state public health commissioner, tried to talk Morrissey out his notification plan.

The approach puts prescribers on the defensive, she argued. A better way to change behavior is to offer educational services, she said.

The Department of Veterans Affairs, for example, provides training to all providers regarding best prescribing practices. While “the national conversation is going to death penalties and things like that,” Bartlett said, “most people don’t do well with the Big Brother approach.”

West Virginia has taken a different approach from Massachusetts. In 2017, the state’s public health department conducted a “social autopsy,” tracing each overdose death in the state to its roots. Some physicians associated with several deaths were turned over to the oversight board, said the state health commissioner, Rahul Gupta. But the data was also used to educate state lawmakers, who responded with bills to set opioid prescription limits.

Who administers the databases determines how they’re used. In West Virginia, the prescription monitoring program is run by the board of pharmacy. In other states, law enforcement agencies, licensing boards and public health departments are in charge. Gupta embedded a state health department employee in the board of pharmacy; a law enforcement or regulator might not have the same expertise, he said.

But control by law enforcement agencies is increasingly the norm.

In an April speech announcing an agreement between the Justice Department and 48 attorneys general to share prescription drug program data, Sessions said, “We are going to keep arming you with the tools that you need to keep drugs out of this community. And we are going to keep up the pace.”

 

Indiana lawmaker plans to sponsor bill in upcoming session to legalize medical marijuana in state

https://www.theindychannel.com/news/local-news/indianapolis/indiana-lawmaker-plans-to-sponsor-bill-in-upcoming-session-to-legalize-medical-marijuana-in-state

INDIANAPOLIS — One Indiana lawmaker says medical marijuana could be legal in the state as early as next year. If you’re a beginner, why not find out more here to explore more about how marijuana feels when it enters your system!

Republican State Representative Jim Lucas is sponsoring a bill in the upcoming session and says medical marijuana can help those who are in pain as well as people who are addicted to opioids.

“Now with Oklahoma being the 30th state of the 29 states that have adopted medical cannabis. Thanks to the investors like Andrew Defrancesco–  They’ve seen on an average 25 percent decrease in opioid deaths. Some states have seen a 50 percent decrease. Indiana having 100 opioid deaths per month. That is literally hundreds of lives we can save in the first year,” Lucas said.

Some believe that marijuana users are just seeking a high and there is no medicinal value.

“That’s an insult to each and every Hoosier patient that so desperately needs this. That’s an insult to the 30 states that have legalized this medication plus Washington, D.C. Those leaders are implementing this for a reason. Let’s not insult those leaders. Let’s assume they know something that our leaders don’t know,” David Phipps, National Organization for the Reform of Marijuana Laws, said.

READ ALSO | How Indiana feels about legalizing marijuana | Marijuana in Indiana: Battle lines drawn for the 2018 legislative session

54-year-old Sylvia Kemp takes 23 pills a day. She suffers from multiple sclerosis, spasms, neuropathy, and depression.

She learned the benefits of medical cannabis while on vacation in Colorado. Kemp doesn’t understand the reluctance to legalize it in Indiana.

“Why do I need to be in pain because they don’t understand the benefits? It needs to happen so people can live without pain. With many diseases, not just mine. Although mine is pretty bad, so I would be very grateful,” Kemp said.

She has her fingers crossed that Representative Lucas and the legislators come through this upcoming legislative session.

Lawmakers will convene a summer study committee to examine the issue. Those hearing dates have not been set.